A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 16, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Refractory Solid Tumors

Interventions

DRUG

Eribulin

Given by vein (IV)

DRUG

Irinotecan

Given by vein (IV)

DRUG

Temozolomide

Given by PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER